Page 193 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

8. MITOMYCINE C 149

IYER V.N., SZYBALSKI W., Mitomycins and porfiromycin : chemical mechanism of acti-
vation and cross-linking of DNA, Science, 1964, 145, 55-58.
SZYBALSKI W., IYER V.N., The mitomycins and porfiromycins, in Antibiotics, Springer-
Verlag, New York, 1967, 211-245.
TOMASZ M., H,O, Generation during the redox cycle of mitomycin C and DNA-bound
mitomycin C, Chem.-Biol. Interactions, 1976, 13, 89-97.
FRANCK R.W., TOMASZ M., The chemistry of mitomycins, in The chemistry of antitu-
mouragents, Wilman D.E.V., ed, Chapman and Hall, New York, 1990, 379-394.
TOMASZ M., Mitomycin C : small, fast and deadly (but very selective), Chem. & Bio/.,
1995, 2, 575-579 ; corrigendum ibid, 865.
KUMAR G.S., MUSSER S.M., CUMMINGS J., TOMASZ M., 2,7-Diaminomitosene, a
monofunctional mitomycin C derivative, alkylates DNA in the major groove. Structure
and base-sequence specificity of the DNA adduct and mechanism of the alkylation,
J. Am. Chem. Soc., 1996, 118, 9209-9217.
TOMASZ M., PALOM Y., The mitomycin bioreductive antitumor agents : cross-linking
and alkylation of DNA as the molecular basis of their activity, Pharmacol. Ther., 1997,
76, 73-87.
RAJSKI S.R., WILLIAMS R.M., DNA cross-linking agents as antitumordrugs, Chem. Rev.,
1998, 98, 2723-2795.

ACTIVITÉ, RELATIONS STRUCTURE-ACTIVITÉ
FRANK W., OSTERBERG A.E., Mitomycin C (NSC-26980) - an evaluation of the japa-
nese reports, Cancer Chemother., 1960, 9, 114-119.
KOJIMA R., DRISCOLL J., MANTEL N., GOLDIN A., Sorne structure-activity rela-
tionships formitomycin C(NSC-26980) derivatives in the treatment of L1210leukemia,
Cancer Chemother. Rep. Part 2, 1972, 3, 121-135.
REM ERS W.A., Mitomycins, ln Anticanceragents based on natural product models, Cas-
sady J. M., Douros J.D., ed, Academic Press, New York, 1980, vol. 10, 131-146.
LAMBERT P.A., KANG Y., GREAVES B., PERRY R.R., The importance of DT-diaphorase
in mitomycln C resistance in human colon cancer cell lines, J. Surg. Res., 1998, 80,
177-181.
PERSPECTIVES
HOSHI A., KT-6149, Drugs of Future, 1989, 14, 127-129.
DANISHEFSKY S.J., SCHKERYANTZ J.M., Chemical explorations driven by an enchant-
ment with mitomycinoids - A twenty year account, Synlett, 1995, 475-490.
EO9, Drugs of Future, 1996, 21, 143-151.
TOMASZ M., PALOM Y., The mitomycin bioreductive antitumor agents : cross-linking
and alkylation of DNA as the molecular basis of their activity, Pharmacol. Ther., 1997,
76, 73-87.
PALOMINO E., EO-9, National Institutes of Health, Curr. Opin. Onco/., Endocr. Metab.
Invest. Drugs, 1999, 1, 416-426.